Welcome to our dedicated page for Matinas Biopharm SEC filings (Ticker: MTNB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Matinas BioPharma Holdings, Inc. (MTNB) SEC filings page on Stock Titan brings together the company’s public regulatory disclosures from the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer listed on the NYSE American, Matinas uses filings such as Forms 10-K, 10-Q, and 8-K to report on its business, financial condition, and material corporate events related to its lipid nanocrystal (LNC) platform and lead antifungal candidate MAT2203.
Annual reports on Form 10-K typically provide a detailed description of Matinas’ business, including the development status of MAT2203 as an oral amphotericin B for invasive fungal infections, the broader LNC platform for small molecules and small oligonucleotides, key risk factors, and discussion of liquidity and capital resources. Quarterly reports on Form 10-Q update investors on operating results, research and development spending, and balance sheet items such as cash, cash equivalents, and marketable securities, which are important for a company funding clinical trials and preclinical work.
Current reports on Form 8-K are particularly relevant for tracking near-term changes at Matinas. Recent 8-Ks have disclosed matters such as amendments to the Chief Executive Officer’s employment agreement and retention bonus tied to a potential Change in Control, board and committee appointments and resignations, stockholder approvals of an equity incentive plan and increases in authorized shares, warrant exchange agreements, and a NYSE American noncompliance notice related to the timing of the annual meeting. These filings help clarify how governance, capital structure, and strategic alternatives may affect shareholders.
Investors can also review equity and compensation-related filings, including documents describing the 2025 Equity Incentive Plan and amendments to the certificate of incorporation to increase authorized common stock. On Stock Titan, AI-powered tools summarize lengthy Matinas filings, highlight key terms, and make it easier to locate information on topics such as MAT2203 development plans, LNC platform risks, and corporate transactions, while direct links to Form 4 and other ownership filings allow users to monitor insider and significant holder activity reported to the SEC.
Matinas BioPharma Holdings, Inc. reported a leadership change in its finance function. Following the previously announced resignation of Chief Financial Officer Keith Kucinski effective January 17, 2026, the board appointed Jerome D. Jabbour, the company’s Chairman, President and Chief Executive Officer, as interim Chief Financial Officer effective January 22, 2026.
Jabbour, 51, is a co‑founder of the company and has held senior roles since 2013, including Chief Executive Officer since March 2018 and Chairman of the Board since March 2025. He will also serve as the company’s principal financial officer and principal accounting officer until a successor is appointed or he resigns or is removed. His existing compensation arrangements remain unchanged, and the company states there are no special appointment arrangements, family relationships, or related‑party transactions connected to this role.
Matinas BioPharma Holdings updated the employment agreement of its Chief Executive Officer, Jerome D. Jabbour, through a third amendment. The change extends the deadline for a qualifying Change in Control that would trigger his retention bonus from March 31, 2026 to June 30, 2026. The retention bonus remains the greater of his target annual bonus for the year of the Change in Control or $299,000.
The amendment also splits the retention bonus into two stages: two-thirds payable when Matinas signs a definitive agreement that would result in a Change in Control, and one-third payable immediately before closing, provided he has not resigned without Good Reason or been terminated for Cause. If he resigns for Good Reason or is terminated other than for Cause, the retention bonus becomes payable within ten days and no later than immediately before a Change in Control. Jabbour is guaranteed an annual bonus for 2025 of at least his target bonus, payable by February 1, 2026, and the definitions of Change in Control, Cause, and Good Reason are updated, including adding transactions that materially change the company’s primary business.
Matinas BioPharma Holdings, Inc. reported a planned leadership change. On November 18, 2025, Chief Financial Officer Keith Kucinski informed the company that he intends to resign from his role, effective January 17, 2026, to pursue other opportunities. The company stated that his decision is not due to any disagreement regarding its operations, policies, or practices, indicating an orderly transition rather than a dispute-driven departure.
Matinas BioPharma (MTNB): ownership update — Highbridge Capital Management, LLC filed Amendment No. 2 to Schedule 13G reporting 0% beneficial ownership of Matinas BioPharma common stock. The filing shows 0 shares beneficially owned with 0 sole or shared voting and dispositive power.
The date of event triggering the filing is 09/30/2025. Highbridge certifies the securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Matinas BioPharma Holdings (MTNB) reported Q3 2025 results. The company posted a Q3 net loss of $1.532 million and a nine‑month net loss of $8.433 million as it cut operating costs. Cash and cash equivalents were $5.435 million, with $0.250 million in restricted cash. Management states that cash on hand is not sufficient to fund planned operations beyond the next twelve months, and substantial doubt exists about the company’s ability to continue as a going concern.
Operating expenses fell sharply as R&D dropped to $0 in Q3 (from $2.239 million a year ago) and G&A was $1.577 million (from $2.142 million). A $3.161 million loss from the change in fair value of warrant liability was recognized before the warrants were amended and reclassified to equity. The company raised $3.3 million gross via a private placement of Series C Convertible Preferred Stock and accompanying warrants. Authorized common shares were increased to 500,000,000. Common shares outstanding were 5,901,091 as of September 30, 2025; 6,406,191 were outstanding as of November 6, 2025.
Disclosure controls and procedures were not effective due to an unresolved material weakness, with a remediation plan underway.
Amendment No. 2 to Schedule 13D for Matinas BioPharma Holdings, Inc. (MTNB) reports that Hezbay Holdings LLC and its sole member, Ari Kluger, beneficially own 253,841 common shares, representing 4.99% of 5,086,985 shares outstanding as of August 12, 2025. The Amendment states the Reporting Person withdrew from the previously disclosed Joint Filing Agreement and notes the holdings are subject to a contractual 4.99% ownership restriction. Because of that blocker, the Reporting Person indicates it is currently no longer required to file reports under Rule 13d. The Amendment incorporates this change into Item 6 and files no new exhibits.
Matinas BioPharma Holdings, Inc. (MTNB) Schedule 13G shows David E. Lazar reported beneficial ownership of 545,000 shares, equal to 9.81% of the company’s common stock based on 5,553,651 shares outstanding. The filing states those shares were beneficially owned as of the close of business on August 15, 2025. The cover data indicates 0 sole voting and dispositive power and 545,000 shares held with shared voting and dispositive power. The Reporting Person is identified as a registered investment adviser type (IA) and lists principal business address in Panama City, Panama. The filing includes a certification that the holdings were not acquired to influence control of the issuer.
Matinas BioPharma Holdings, Inc. entered into Warrant Exchange Agreements with certain holders of warrants to purchase an aggregate of 466,666 shares of its common stock, each warrant having a current exercise price of $17.50. On August 15, 2025, the company completed an exchange in which it issued one share of common stock for each warrant, resulting in 466,666 new common shares being issued. The exchanged warrants, originally issued on April 5, 2024, were cancelled so that no further shares are issuable under them. The common shares issued in this exchange relied on the exemption from registration provided by Section 3(a)(9) of the Securities Act.
Highbridge Capital Management reported beneficial ownership of 466,667 shares of Matinas BioPharma Holdings common stock, representing 8.4% of the outstanding class based on 5,086,985 shares outstanding. The reported shares are issuable upon exercise of warrants held by Highbridge Funds and are held on behalf of those funds, with Highbridge Tactical Credit Master Fund, L.P. identified as having rights to more than 5% of the class. The filing clarifies that these securities were acquired and are held in the ordinary course of business and not for the purpose of changing control.
Matinas BioPharma Holdings, Inc. (MTNB) filed an 8-K (Item 5.03) reporting a Certificate of Amendment that doubles its authorized common stock to 500 million shares, up from 250 million. The amendment was approved at the 23 Jun 2025 annual meeting and became effective upon filing with Delaware on 6 Aug 2025.
No shares were issued and no financial statements accompanied the filing. The increased authorization gives the company added flexibility to raise capital, fund strategic transactions or expand equity-based compensation plans. However, future issuances could dilute existing shareholders and pressure per-share metrics. Investors should track subsequent financings or option grants that may utilize the newly authorized shares.